<DOC>
	<DOCNO>NCT03012828</DOCNO>
	<brief_summary>This study investigate effect single oral dose moxidectin QT interval associate moxidectin plasma concentration . The effect moxidectin ECG interval , safety , also assess , preliminary pharmacokinetics metabolism</brief_summary>
	<brief_title>Effect Single Oral Dose Moxidectin Cardiac QT Interval Healthy Volunteers</brief_title>
	<detailed_description>Moxidectin develop treatment Onchocerciasis ( river blindness ) , serious , debilitate , disease cause parasitic worm , Onchocerca volvulus . Five dose level moxidectin administer healthy volunteer ECG assessment undertaken pre-specified pharmacokinetic time point correlate QT interval moxidectin concentration plasma .</detailed_description>
	<mesh_term>Milbemycin</mesh_term>
	<criteria>1 . Healthy male 18 50 year age ( inclusive ) ; 2 . Body mass index ( BMI ) 18 30 kg/m2 ( inclusive ) minimum weight 50 kg ( 110 lb ) ; 3 . Biologically surgically sterile must commit use reliable method birth control , opinion investigator , Screening duration study ; 4 . Willing able give write informed consent . 1 . Unwilling abstain alcohol , caffeine , xanthine contain product , Seville oranges , grapefruit juice , fish liver oil within 72 hour Check ( Day 1 ) throughout inpatient period study ; 2 . Less 1 bowel movement every 24 hour absence laxative , suppository , enema use month Screening ; 3 . Abnormal fecal consistency within 24 hour Check ( Day 1 ) ; 4 . Clinically relevant abnormal finding medical history , clinical laboratory test result , vital sign measurement , safety 12 lead ECG result , physical examination Screening Baseline , opinion investigator , would interfere dose , jeopardize safety subject , impact validity study result ; 5 . History clinically significant dermatologic , gastrointestinal , renal , hepatic , neurologic , hematologic , endocrine , oncologic , pulmonary , immunologic , psychiatric , cardiovascular disease condition , opinion investigator , would interfere dose , jeopardize safety subject , impact validity study result ; 6 . History hypersensitivity allergic reaction ivermectin , moxidectin , ingredient study drug describe Investigator 's Brochure ; 7 . Any condition may affect oral drug absorption ( eg , previous surgery gastrointestinal tract include removal part stomach , bowel , liver , gall bladder , pancreas ) ; 8 . History risk factor torsades de pointes , include unexplained syncope , know long QT syndrome , heart failure , myocardial infarction , angina , clinically significant abnormal laboratory assessment include hypokalemia , hypercalcemia , hypomagnesemia . Subjects also exclude family history long QT syndrome Brugada syndrome ; 9 . A sustained supine systolic blood pressure &gt; 150 mm Hg &lt; 90 mm Hg supine diastolic blood pressure &gt; 95 mm Hg &lt; 50 mm Hg Screening Check ( Day 1 ) . Blood pressure may retested twice supine position . The blood pressure abnormality consider sustain either systolic diastolic blood pressure value outside state limit 3 assessment , subject randomize ; 10 . A resting heart rate ( HR ) &lt; 40 beat per minute ( bpm ) &gt; 100 bpm vital sign measure Screening Check ( Day 1 ) ; 11 . An uninterpretable abnormal screening ECG indicate second third degree atrioventricular block , 1 following : QRS interval &gt; 110 millisecond ( msec ) ; QT interval correct Fridericia 's formula ( QTcF ) &gt; 450 msec ; PR interval &gt; 200 msec ; rhythm sinus rhythm interpret investigator clinically significant ; 12 . Concomitant use prescription medication , include medication know prolong correct QT interval ( QTc ) herbal preparation , within 14 day 5 halflives ( whichever longer ) study drug dosing , use counter ( OTC ) medication vitamin within 7 day study drug dosing ; 13 . Received investigational drug 30 day , 5 half life study drug ( whichever longer ) , Check ( Day 1 ) planning receive another investigational drug time study ; 14 . History presence alcohol abuse ( define consumption 210 mL alcohol per week , equivalent fourteen 4 ounce [ oz ] glass wine fourteen 12 oz cans/bottles beer wine cooler per week ) within 6 month Screening positive alcohol test Screening Checkin ( Day 1 ) ; 15 . History presence substance abuse within past 2 year positive drug screen test Screening Check ( Day 1 ) ; 16 . Current use use tobacco nicotinecontaining product ( eg , cigarette , cigar , chew tobacco , snuff , etc . ) within 14 day study drug dosing ; 17 . Blood donation significant blood loss within 30 day Checkin ( Day 1 ) donate plasma within 7 day Checkin ( Day 1 ) ; 18 . Presence hepatitis B surface antigen antibody human immunodeficiency virus ( HIV ) hepatitis C virus Screening ; 19 . Poor venous access arm ; 20 . Unable understand verbal write English language certify translation inform consent form available ; 21 . For reason , deem investigator medically qualify designee inappropriate study , include subject unable communicate cooperate investigator , and/or unwilling comply protocol define procedure complete study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>